NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.

RecruitingN/A

Sponsor: University Hospital Augsburg

Conditions: Characteristics Disease, Metastatic Cancer, Solid Tumor

Countries: Germany

A prospective observational trial of patients with metastatic cancer of various entities which aims at both clarifying the significance of liquid biopsy and establishing a foundation for translational research.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Written informed consent
* Age ≥ 18 years
* Histopathologically confirmed metastatic or locally advanced cancer
* No curative treatment options, except for germ cell tumors
* Written Agreement to be followed up at Augsburg University Medical Center
* Signed written informed consent for the Biobank Augsburg (Biobank-A)
* Willing to undergo treatment according to standard of care
* Availability or anticipated availability of tumor tissue at time point of inclusion
* Anticipated life expectancy of at least 3 months at time point of trial inclusion

Exclusion Criteria:

* Psychological condition that would preclude informed consent
* Additional tumor treatment between acquisition of tumor tissue and trial inclusion

Locations (1)

Augsburg, Bavaria, Germany